行情

PIRS

PIRS

Pieris Pharms
NASDAQ

实时行情|Nasdaq Last Sale

3.310
-0.040
-1.19%
盘后: 3.310 0 0.00% 16:00 01/17 EST
开盘
3.390
昨收
3.350
最高
3.420
最低
3.230
成交量
28.07万
成交额
--
52周最高
6.04
52周最低
2.440
市值
1.63亿
市盈率(TTM)
-4.6580
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PIRS 新闻

  • 沪指震荡上扬 中国央行4天投放1.1万亿
  • 新浪财经.28分钟前
  • 低波动率延续 新年迄今股债汇市场一个比一个平静!
  • 环球外汇网.1小时前
  • 不甘心5G落后,日本拟2030年实现“6G通信”
  • 参考消息.2小时前
  • 这只基金去年击败99%同行 它的成功秘诀是……
  • 环球外汇网.3小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

PIRS 简况

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
展开

Webull提供Pieris Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。